# Neurophet Appoints Leading U.S. Dementia Imaging Expert Dr. Ana M. Franceschi as Scientific Advisor

- Link: https://www.thailand-business-news.com/pr-news/neurophet-appoints-leading-u-s-dementia-imaging-expert-dr-ana-m-franceschi-as-scientific-advisor
- Published: 2026-09-03T20:00:00+07:00
- Author: PR Newswire

|   |

 ◦ Dr. Franceschi currently serves as Director of Dementia Imaging and Director 
   of Molecular Neuroimaging at Northwell Health, where she has led advances in 
   brain MRI and PET imaging technologies
 ◦ Neurophet aims to strengthen the clinical evidence for its key products and accelerate
   its expansion into the North American market, enhancing its global business competitiveness

SEOUL, South Korea, Sept. 3, 2026 /PRNewswire/ — Neurophet (Co-CEOs Jake Junkil 
Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain
disorders diagnosis and treatment, announced today that it has appointed Ana M. 
Franceschi, MD, PhD, a globally recognized expert in dementia imaging, as a scientific
advisor.

 [⌊Neurophet Appoints Leading U.S. Dementia Imaging Expert Dr. Ana M. Franceschi as Scientific Advisor⌉](https://mmx.prnasia.com/media/MS1980218/20260902022854EDT_image_1.jpg?id=OA2925231&p=medium600)

Neurophet Appoints Leading U.S. Dementia Imaging Expert Dr. Ana M. Franceschi as
Scientific Advisor

Dr. Franceschi is a globally renowned expert with more than 20 years of experience
spanning clinical practice, research, and hospital-based care in the field of neuroimaging.
She is widely recognized for her expertise in magnetic resonance imaging (MRI) and
positron emission tomography (PET) for neurodegenerative diseases, including Alzheimer’s
disease.

Dr. Franceschi currently serves as Director of Dementia Imaging and Director of 
Molecular Neuroimaging at Northwell Health, which operates an extensive healthcare
network primarily across the New York metropolitan area. In this role, she has led
advances in brain MRI and PET imaging technologies for dementia and other neurodegenerative
diseases. She also serves as an associate professor of radiology at Lenox Hill Hospital,
Donald and Barbara Zucker School of Health at Hofstra/Northwell, where she has built
extensive clinical expertise while continuing to conduct research in the field.

Dr. Franceschi is a key member of the Imaging Workgroup of ALZ-NET, which is sponsored
by the Alzheimer’s Association and operated and managed by the American College 
of Radiology (ACR). In addition, she serves as Chair of the ACR Neuroradiology Research
Committee, Chair of the ACR Neuro Commission Dementia Committee, Secretary of the
ISMRM PET/MRI Study Group, on the Board of Directors of the Brain Advisory Committee
of the SNMMI, and on the leadership team of the ASNR Alzheimer Disease, ARIA and
Dementia Study Group.

Through the appointment of Dr. Franceschi as a scientific advisor, Neurophet plans
to expand the clinical applications of its brain imaging analysis technologies and
leverage its global clinical network, particularly in North America, to broaden 
collaborations with leading medical institutions.

"Neurophet’s AI-powered brain imaging analysis solutions have established global
competitiveness in imaging analysis related to the prescription of Alzheimer’s disease
treatments," said Dr. Franceschi. "I look forward to actively contributing to the
generation of meaningful clinical evidence for Neurophet’s key products in real-
world clinical settings."

"Dr. Franceschi is one of the world’s leading experts in brain MRI and PET imaging
analysis," said Jake Junkil Been, Co-CEO of Neurophet. "With her appointment as 
a scientific advisor, we aim to strengthen our clinical competitiveness on a global
scale and expand the foundation for our international business growth, particularly
in the U.S. market."

**About Neurophet**

Neurophet specializes in developing solutions for diagnosis support, treatment guides,
and treatment devices targeting brain disorders based on cutting-edge artificial
intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil
Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.

Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative
Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software
for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer’s
Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking
treatment efficacy and side effects, and Multiple Sclerosis image analysis software"
Neurophet AQUA MS".

Neurophet has set its top priority to helping patients suffering from brain disorders.
Based on expertise in neuroscience, Neurophet will continue to challenge and grow
to explore the human brain’s health and pioneer solutions for brain diseases with
AI technology.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Neurophet Appoints Leading U.S. Dementia Imaging Expert Dr. Ana M. Franceschi as Scientific Advisor ](http://www.prnasia.com/story/archive/5039052_CN39052_0?rand=184833)